Project 3

Neuroimaging

Project 3 focuses on identifying imaging-based neural signatures associated with COVID-19-related cognitive impairment and downstream ADRD risk.

Project framing

Overview

This project uses volumetric, surface-based, and tract-based neuroimaging measures to investigate structural and systems-level changes associated with cognitive decline after SARS-CoV-2 exposure.

The goal is to identify reproducible imaging markers that can be interpreted alongside clinical, genetic, and biomarker findings across the broader program.

Scientific role

Why imaging matters

Neuroimaging offers a bridge between symptoms and biology, helping the consortium study whether cognitive changes map onto measurable patterns in brain structure and function.

Research focus

Aim 1

Identify neural signatures

Identify group-level imaging signatures associated with COVID-19-related cognitive impairment.

Aim 2

Compare imaging-derived metrics

Compare imaging-derived metrics across participants with differing cognitive and exposure histories.

Aim 3

Support integrated interpretation

Support integrated interpretation with biomarker, genetic, and epidemiological results across ISAVRAD.

Contribution

Study contribution

Project 3 helps determine whether COVID-19-associated cognitive impairment leaves a measurable neural footprint that can be studied longitudinally and compared across populations.

Program fit

Program alignment

The imaging work is designed to complement the consortium’s clinical, biomarker, and genomic efforts, making it easier to connect observed brain changes with broader mechanisms of risk and progression.